Trastuzumab Deruxtecan

Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.

We know the NICE’s decision to not recommend Enhertu for use in the treatment of HER-2 low metastatic and unresectable breast cancer, has come as a blow to many women and their families. We understand that the NICE and NHS England have already sought to apply as much flexibility as they can in their considerations of Enhertu for HER2-low breast cancer and have made it clear to the companies that their pricing of the drug remains the main obstacle to access.

The Government wants to see a deal reached to make Enhertu available. The NICE and NHS England remain open to considering an improved offer from the companies through the rapid review process, and we strongly encourage the companies to come back to the table.

The NICE does recommend Enhertu (trastuzumab deruxtecan) in advanced breast cancer for treating HER2-positive unresectable or metastatic breast cancer after one or more anti-HER 2 treatments.